Video

Findings help investigators understand how FDA-approved AGN-19058 behaves

Author(s):

Kassi Filkins
Conferences|ASCRS

George Waring, MD, discusses the findings of a retrospective study on Allergan’s AGN-190584 for the treatment of presbyopia.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
(Image credit: Ophthalmology Times) World Cornea Congress IX: Epi-on and accelerated crosslinking with Kenneth Beckman, MD
Related Content
CIME 2025 unveils a galaxy of innovation in modern eye care
April 19th 2025

CIME 2025 unveils a galaxy of innovation in modern eye care

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

ISO issues new standards for presbyopia-correcting IOL classification
April 17th 2025

ISO issues new standards for presbyopia-correcting IOL classification

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Tenpoint Therapeutics submits NDA application to FDA for BRIMOCHOL PF for the treatment of presbyopia
April 8th 2025

Tenpoint Therapeutics submits NDA application to FDA for BRIMOCHOL PF for the treatment of presbyopia

(Image courtesy of the Australian Society of Ophthalmologists)
April 8th 2025

Breaking barriers: Australian Society of Ophthalmologists’ first woman CEO steps up

© 2025 MJH Life Sciences

All rights reserved.